Management of patients with upper urinary tract transitional cell carcinoma.
about
Why are upper tract urothelial carcinoma two different diseases?Three-dimensional imaging of ureter with endoscopic optical coherence tomographyActivation of the PI3K/AKT pathway induces urothelial carcinoma of the renal pelvis: identification in human tumors and confirmation in animal models.Endoscopic management of upper tract transitional cell carcinomaRadiotherapy may improve overall survival of patients with T3/T4 transitional cell carcinoma of the renal pelvis or ureter and delay bladder tumour relapseRisk factors associated with ineligibility of adjuvant cisplatin-based chemotherapy after nephroureterectomy.Endoscopic versus open approach of bladder cuff and distal ureter in the management of upper urinary tract transitional cell carcinomaMitomycin C instillation following ureterorenoscopic laser ablation of upper urinary tract carcinoma.Nephron-sparing management vs radical nephroureterectomy for low- or moderate-grade, low-stage upper tract urothelial carcinoma.Predictive factors of recurrence and survival of upper tract urothelial carcinomas.Clinicopathological prognostic factors for upper tract urothelial carcinoma.Endoscopic management of upper urinary tract urothelial carcinoma.Bladder cancer following upper tract urothelial carcinoma.Retroperitoneal lymph nodes in transitional cell carcinoma of the kidney and ureter.Upper urinary tract urothelial carcinoma with loco-regional nodal metastases: insights from the Upper Tract Urothelial Carcinoma Collaboration.Treatment of metastatic renal cell carcinoma and renal pelvic cancer.The role of systemic chemotherapy in management of upper tract urothelial cancer.Prognostic impact of the expression of ALDH1 and SOX2 in urothelial cancer of the upper urinary tract.Prognostic value of systemic inflammatory responses in patients with upper urinary tract urothelial carcinoma.Validation of the Pretreatment Neutrophil-to-Lymphocyte Ratio as a Prognostic Factor in a Large Cohort of Chinese Patients with Upper Tract Urothelial Carcinoma.Complications Following Radical Nephroureterectomy.Endoscopic management of upper-tract urothelial carcinoma.Preoperative nomogram to predict the likelihood of complications after radical nephroureterectomy.Post-operative urothelial recurrence in patients with upper urinary tract urothelial carcinoma managed by radical nephroureterectomy with an ipsilateral bladder cuff: Minimal prognostic impact in comparison with non-urothelial recurrence and other c[Urothelial carcinoma of the upper urinary tract: clinical and pathological criteria and their predictive implications after radical nephroureterectomy].Experimental and clinical evaluation of transperitoneal laparoscopic ureteronephrectomy in dogs.Rationale and timing of perioperative chemotherapy for upper-tract urothelial carcinoma.Adjuvant chemotherapy after radical nephroureterectomy does not improve survival in patients with upper tract urothelial carcinoma: a joint study by the European Association of Urology-Young Academic Urologists and the Upper Tract Urothelial CarcinoConservative nephron-sparing treatment of upper-tract tumors.Extraurothelial recurrence after radical nephroureterectomy: preoperative predictors and survival.
P2860
Q28074161-061C08EE-F628-40F9-B9DC-B5A98D380E95Q30500077-8CF081FE-F51D-4A98-942F-BD3E97562749Q33511579-C9C033F0-C4C8-453B-837F-24368C3E42E6Q33705155-5A1DD60D-508B-4FEB-B41E-405FC97A3A75Q33960861-EB603440-5518-4582-A8B8-1F53646D3B15Q34415314-75C80E2A-5C16-49DE-BF97-2CAB0462C113Q34667975-6F77818D-91A0-4C1D-B2A9-F6FE3DA8CB3CQ34992162-2FBD5430-94A4-42E4-9C5C-E91B5883481FQ35801387-E56555B0-28D1-4B8D-BA7E-CC961CA18634Q36478530-D9324C55-4556-490A-BABF-E0F03EC2E7EDQ36840704-0C9B1102-43EB-4540-B15F-99B57C1AB657Q37025437-4B43179B-39D1-4E02-8272-85032479C7D8Q37038905-00389994-16DD-4BB5-AA38-0419F2707506Q37384749-178BF0FE-5272-439D-A753-24815AB8E8E4Q37844679-A565ACCD-7E58-4E4F-8198-9CB8F314C372Q37863582-B3BB2FCD-C1F4-48EB-8433-2317E3CA2B7DQ38076327-FEDF0AB6-4EBE-4B6F-B727-5073E4B44A84Q38401641-BEBA84F4-1760-4097-A04E-3AF04FA212EEQ38429539-C9004B45-7708-4EEE-860D-2587636A9D3FQ38610684-76EC28BF-2418-459E-A050-73692E813B5BQ38770367-87948C2A-74AD-4C8D-B0B5-3B796887F199Q39290229-7F5030BF-1F2F-4BE1-BF5A-0BBA9E44C2F0Q40691705-FAC88C88-92AF-4BA2-B404-44A1E3CEA9E7Q42673228-4C402F29-0A9B-4D3D-A9DB-529DE27BC42CQ44321330-2FDC2BC5-9ECE-4177-A9D9-F8816C273173Q46364075-90EE4440-BA22-4A52-9E97-CB4E2A3E1E44Q46528648-1208EED0-2AD0-4CFF-831B-ABCCD5211697Q47936737-EA783F82-6610-4F70-98EB-5675F0DA7DF3Q53123230-261F3F32-0BE1-4D73-9BA5-FFA15E9343E9Q53578286-558C3794-91FA-48E2-9B4B-906393FDA7D7
P2860
Management of patients with upper urinary tract transitional cell carcinoma.
description
2007 nî lūn-bûn
@nan
2007 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Management of patients with upper urinary tract transitional cell carcinoma.
@ast
Management of patients with upper urinary tract transitional cell carcinoma.
@en
Management of patients with upper urinary tract transitional cell carcinoma.
@nl
type
label
Management of patients with upper urinary tract transitional cell carcinoma.
@ast
Management of patients with upper urinary tract transitional cell carcinoma.
@en
Management of patients with upper urinary tract transitional cell carcinoma.
@nl
prefLabel
Management of patients with upper urinary tract transitional cell carcinoma.
@ast
Management of patients with upper urinary tract transitional cell carcinoma.
@en
Management of patients with upper urinary tract transitional cell carcinoma.
@nl
P356
P1476
Management of patients with upper urinary tract transitional cell carcinoma
@en
P2093
Douglas S Scherr
P2888
P304
P356
10.1038/NCPURO0875
P407
P50
P577
2007-08-01T00:00:00Z
P6179
1005508144